SCHEMBL18970271

SCHEMBL18970271

Cc1cc2cc(C(C)C)ccc2c(N)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SCN4A P35499 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
ALOX12 P18054 1/20 0.39
HTT P42858 1/20 0.39
HIF1A Q16665 1/20 0.39
TBK1 Q9UHD2 2/20 0.38
DHFR P00374 2/20 0.38
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
IKBKE Q14164 1/20 0.36
TRPA1 O75762 1/20 0.36
PTGS1 P23219 1/20 0.36
CACNA1C Q13936 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27251653 0.81 LMNA (0.39) NPC1RAB9ASCN4ASMN1; SMN2TBK1
SCHEMBL27592978 0.77 KDM4E (0.47) SMN1; SMN2ALDH1A1DHFRLMNAKDM4E
SCHEMBL15676703 0.77 LMNA (0.47) SMN1; SMN2ALDH1A1GAALMNAKDM4E
Hydrochloric Acid SCHEMBL3761973 0.76 KDM4E (0.46) ALDH1A1DHFRLMNAKDM4EHSD17B10
SCHEMBL12546016 0.75 ROCK1 (0.53) NPC1RAB9ASCN4ASMN1; SMN2ALDH1A1
SCHEMBL17253660 0.75 ROCK1 (0.38) ALDH1A1TBK1LMNAIKBKEKDM4E
SCHEMBL393406 0.74 HTT (0.43) SMN1; SMN2ALDH1A1GAAHTTDHFR
SCHEMBL7142868 0.74 USP7 (0.37) NPC1RAB9AALDH1A1GAAHTT
SCHEMBL19756415 0.74 NPC1 (0.42) NPC1RAB9ASCN4ASMN1; SMN2ALDH1A1
SCHEMBL7141013 0.71 ROCK1 (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166560-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166560-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 NPC1 3968/4885RAB9A 818/4885SCN4A 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.